Boston Scientific stock steadies near 48 dollars as guidance and cyber risks shape sentiment
Published on 09/01/2026 at 22:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific Corporation (ISIN US10117L1017) stock is changing hands around 48.35 dollars as of September 1, 2026, leaving the medical device maker in a narrow range after recent volatility around cyber risks and product recalls.
Q2 2026 results and guidance support the story
According to recent data compiled by MarketBeat, Boston Scientific last reported quarterly earnings for Q2 2026 on July 29, 2026.
For that quarter, the company delivered earnings per share of 0.86 dollars, beating consensus estimates of 0.83 dollars by 0.03 dollars, while revenue reached 5.44 billion dollars against expectations of 5.38 billion dollars.
The same source notes that Boston Scientific’s Q2 2026 revenue grew 7.5 percent year on year, with the prior year’s quarter at 5.06 billion dollars and earnings per share of 0.75 dollars, underscoring a combination of top line growth and margin expansion.
On profitability, the company generated a net margin of 17.50 percent and a return on equity of 19.28 percent in Q2 2026, figures that underline a capital efficient business model supported by recurring device and consumable sales.
Looking ahead, Boston Scientific has set Q3 2026 guidance in a range of 0.800 to 0.820 dollars earnings per share and fiscal year 2026 guidance between 3.280 and 3.320 dollars earnings per share, signaling expectations for continued growth despite operational challenges.
Stock price, trading activity and analyst view
Shares of Boston Scientific opened at 48.35 dollars on September 1, 2026, based on market data cited by MarketBeat’s latest institutional holding alerts.
Over the past 50 trading days, the stock’s moving average stands at 46.65 dollars, while the 200 day moving average is reported at 56.35 dollars, illustrating that the current price is modestly above its short term average but still below longer term levels.
Intraday data from Yahoo Finance shows Boston Scientific trading in a band between 47.95 and 48.94 dollars on September 1, 2026, with around 3.56 million shares changing hands in recent most active trading statistics.
Analyst sentiment remains constructive: a recent overview highlights a consensus rating of Strong Buy with a price target consensus around 61.00 dollars, implying roughly 30 percent upside from current levels and reflecting confidence in the company’s pipeline and earnings trajectory.
In addition, BofA Securities recently reiterated a buy rating on Boston Scientific with a target price of 54 dollars, a level modestly above the current trading band that anchors short term expectations for many investors.
For investors, that setup translates into a stock that is still below some fair value estimates, with at least one analysis quoting an implied value north of 100 dollars per share based on long term growth scenarios, even though such figures naturally carry more uncertainty.
Cybersecurity incident and recall concerns shape risk perception
A key reason Boston Scientific stock has seen volatility in late August and early September 2026 is the company’s exposure to broader healthcare cyberattack and recall headlines.
On September 1, 2026, Reuters reported that oncology firm Novocure disclosed a cybersecurity incident that exposed records of more than 1,400 United States patients, adding to a growing series of attacks on healthcare entities including device makers such as Boston Scientific.
In parallel, a detailed article on SOFX describes how a cyberattack knocked Boston Scientific offline, leaving some newly implanted cardiac devices unable to activate remote monitoring for a period.
That report notes that Boston Scientific shares fell about 4 percent in morning trading on August 26, 2026 and closed at 48.17 dollars, down 3.38 percent on volume of 31.8 million shares, approximately 48 percent above the stock’s three month average trading volume.
The same day, a Class I recall affecting certain ENROUTE transcarotid devices was disclosed, adding pressure to the share price and amplifying investor focus on operational risk and regulatory scrutiny.
For investors, the combination of robust earnings and guidance on the one hand and cyber and recall risks on the other creates a nuanced picture, where risk management and remediation steps are likely to play as large a role in sentiment as headline financial metrics.
Representative product: cardiac rhythm management devices
Boston Scientific is best known to many patients and physicians for its cardiac rhythm management systems, including implantable cardioverter defibrillators and pacemakers that help manage arrhythmias.
These devices often support remote monitoring capabilities, a segment directly referenced in recent cyberattack coverage, and contribute materially to revenue in the company’s cardiovascular portfolio.
Historically, device and related service revenue from rhythm management and other cardiovascular products has made up a significant share of Boston Scientific’s overall revenue, providing recurring demand in developed markets and growth opportunities in emerging markets.
Stock level and investor takeaway
As of September 1, 2026, Boston Scientific stock trades around 48.35 dollars on the New York Stock Exchange, with recent ranges between approximately 47.95 and 48.94 dollars and support near its 50 day moving average of 46.65 dollars.
For investors, the key question is less about the precise day to day price move and more about how the company balances strong Q2 2026 earnings, guidance for continued expansion and active management of cybersecurity and recall risks in the months ahead.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US10117L1017
- Ticker: BSX
- Trading venue: NYSE
- Price (as of September 1, 2026): 48.35 USD
- Market capitalization: 70,000,000,000 USD (as of September 1, 2026)
- Sector / Industry: Health Care Equipment
- Index membership: S&P 500
